CMPD Licensing, LLC (“CMPD”) holds numerous patents issued and pending in the United States.
- US Patent 8,327,610 B1
- US Patent 8,464,498 B1
- US Patent 8,663,663 B1
- US Patent 9,078,853 B2
- US Patent 9,186,319 B2
- US Patent 9,271,989 B2
- US Patent 9,468,601 B2
- US Patent 9,468,599 B2
- US Patent 9,592,241 B2
- US Patent 9,707,229 B2
- US Patent 9,717,748 B2
- US Patent 9,724,315 B2
- US Patent 9,724,294 B2
- US Patent 9,925,141 B2
- US Patent 9,962,391 B2
- US Patent 9,999,604 B2
- US Patent 10,064,949 B2
- US Patent 10,105,342 B2
- US Patent 10,105,381 B2
- US Patent 10,231,924 B2
This non-exhaustive list of patents does not address numerous patents-pending.
A licensee might be a pharmacy that: (a) either compounds or does not compound, (b) does or does not have a sales division, or (c) serves its local community only or instead a larger area through mailing prescriptions.
In addition to the obvious benefit of alleviating concerns about being engaged on potential infringement of CMPD’s patents, licensees may also receive additional services and benefits including, but not limited to, the following:
- Access to a compounded formula containing Diclofenac Sodium 1.5%, Lidocaine 2.5%, Prilocaine 2.5% that meets USP-51, USP-61, and USP-62 requirements,
- Education related to compounded formula containing Diclofenac Sodium 1.5%, Lidocaine 2.5%, Prilocaine 2.5% usage and documentation supporting the appropriateness of this approach,
- Education related to clinically appropriate approaches to nasal symptom management (both compounded and non-compounded treatment options),
- Assistance on controlling your cost-of-goods,
- Guidance on recommended “best practices” for compliance-driven pharmacy operations,
- Appropriate utilization of non-compounded Lidocaine 2.5%-Prilocaine 2.5% Cream,
- Generic-Effective-Rate education,
- Suggestions to mitigate fraud, waste, and abuse concerns of many industry payers and regulators, such as avoidance of: (a) various suspect creams and gels used for topical pain management, (b) certain high-priced generic tablets or capsules used for muscle relaxation or nasal / allergy symptoms, (c) various inappropriate non-soluble capsules, creams, and ointments often used in bath-irrigation or hydrotherapy delivery methodologies, and (d) manufacturer or wholesaler-sponsored “copay cards” that often run contrary to requirements for federal plan sponsors and/or provider manual language, and
- Potential access to additional addenda to the Licensing Agreement that would allow ordering of limited-access items such as BASSA-GEL™.